Beneficial effects of troxerutin on metabolic disorders in non-obese model of metabolic syndrome.

<h4>Background</h4>Troxerutin (TRX) has a beneficial effect on blood viscosity and platelet aggregation, and is currently used for the treatment of chronic varicosity. Recently, TRX can improve lipid abnormalities, glucose intolerance and oxidative stress in high-fat diet-induced metabol...

Full description

Bibliographic Details
Main Authors: Hana Malinska, Martina Hüttl, Olena Oliyarnyk, Irena Markova, Martin Poruba, Zuzana Racova, Ludmila Kazdova, Rostislav Vecera
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0220377
id doaj-71daab0ab7594bec8c1d6c1d56e3c3c3
record_format Article
spelling doaj-71daab0ab7594bec8c1d6c1d56e3c3c32021-03-04T10:26:18ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01148e022037710.1371/journal.pone.0220377Beneficial effects of troxerutin on metabolic disorders in non-obese model of metabolic syndrome.Hana MalinskaMartina HüttlOlena OliyarnykIrena MarkovaMartin PorubaZuzana RacovaLudmila KazdovaRostislav Vecera<h4>Background</h4>Troxerutin (TRX) has a beneficial effect on blood viscosity and platelet aggregation, and is currently used for the treatment of chronic varicosity. Recently, TRX can improve lipid abnormalities, glucose intolerance and oxidative stress in high-fat diet-induced metabolic disorders. In this study, we tested the effect of TRX on metabolic syndrome-associated disorders using a non-obese model of metabolic syndrome-the Hereditary Hypertriglyceridaemic rats (HHTg).<h4>Methods</h4>Adult male HHTg rats were fed standard diet without or with TRX (150 mg/kg bwt/day for 4 weeks).<h4>Results</h4>Compared to untreated rats, TRX supplementation in HHTg rats decreased serum glucose (p<0.05) and insulin (p<0.05). Although blood lipids were not affected, TRX decreased hepatic cholesterol concentrations (p<0.01) and reduced gene expression of HMGCR, SREBP2 and SCD1 (p<0.01), involved in cholesterol synthesis and lipid homeostasis. TRX-treated rats exhibited decreased lipoperoxidation and increased activity of antioxidant enzymes SOD and GPx (p<0.05) in the liver. In addition, TRX supplementation increased insulin sensitivity in muscles and epididymal adipose tissue (p<0.05). Elevated serum adiponectin (p<0.05) and decreased muscle triglyceride (p<0.05) helped improve insulin sensitivity. Among the beneficial effects of TRX were changes to cytochrome P450 family enzymes. Hepatic gene expression of CYP4A1, CYP4A3 and CYP5A1 (p<0.01) decreased, while there was a marked elevation in gene expression of CYP1A1 (p<0.01).<h4>Conclusion</h4>Our results indicate that TRX improves hepatic lipid metabolism and insulin sensitivity in peripheral tissues. As well as ameliorating oxidative stress, TRX can reduce ectopic lipid deposition, affect genes involved in lipid metabolism, and influence the activity of CYP family enzymes.https://doi.org/10.1371/journal.pone.0220377
collection DOAJ
language English
format Article
sources DOAJ
author Hana Malinska
Martina Hüttl
Olena Oliyarnyk
Irena Markova
Martin Poruba
Zuzana Racova
Ludmila Kazdova
Rostislav Vecera
spellingShingle Hana Malinska
Martina Hüttl
Olena Oliyarnyk
Irena Markova
Martin Poruba
Zuzana Racova
Ludmila Kazdova
Rostislav Vecera
Beneficial effects of troxerutin on metabolic disorders in non-obese model of metabolic syndrome.
PLoS ONE
author_facet Hana Malinska
Martina Hüttl
Olena Oliyarnyk
Irena Markova
Martin Poruba
Zuzana Racova
Ludmila Kazdova
Rostislav Vecera
author_sort Hana Malinska
title Beneficial effects of troxerutin on metabolic disorders in non-obese model of metabolic syndrome.
title_short Beneficial effects of troxerutin on metabolic disorders in non-obese model of metabolic syndrome.
title_full Beneficial effects of troxerutin on metabolic disorders in non-obese model of metabolic syndrome.
title_fullStr Beneficial effects of troxerutin on metabolic disorders in non-obese model of metabolic syndrome.
title_full_unstemmed Beneficial effects of troxerutin on metabolic disorders in non-obese model of metabolic syndrome.
title_sort beneficial effects of troxerutin on metabolic disorders in non-obese model of metabolic syndrome.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2019-01-01
description <h4>Background</h4>Troxerutin (TRX) has a beneficial effect on blood viscosity and platelet aggregation, and is currently used for the treatment of chronic varicosity. Recently, TRX can improve lipid abnormalities, glucose intolerance and oxidative stress in high-fat diet-induced metabolic disorders. In this study, we tested the effect of TRX on metabolic syndrome-associated disorders using a non-obese model of metabolic syndrome-the Hereditary Hypertriglyceridaemic rats (HHTg).<h4>Methods</h4>Adult male HHTg rats were fed standard diet without or with TRX (150 mg/kg bwt/day for 4 weeks).<h4>Results</h4>Compared to untreated rats, TRX supplementation in HHTg rats decreased serum glucose (p<0.05) and insulin (p<0.05). Although blood lipids were not affected, TRX decreased hepatic cholesterol concentrations (p<0.01) and reduced gene expression of HMGCR, SREBP2 and SCD1 (p<0.01), involved in cholesterol synthesis and lipid homeostasis. TRX-treated rats exhibited decreased lipoperoxidation and increased activity of antioxidant enzymes SOD and GPx (p<0.05) in the liver. In addition, TRX supplementation increased insulin sensitivity in muscles and epididymal adipose tissue (p<0.05). Elevated serum adiponectin (p<0.05) and decreased muscle triglyceride (p<0.05) helped improve insulin sensitivity. Among the beneficial effects of TRX were changes to cytochrome P450 family enzymes. Hepatic gene expression of CYP4A1, CYP4A3 and CYP5A1 (p<0.01) decreased, while there was a marked elevation in gene expression of CYP1A1 (p<0.01).<h4>Conclusion</h4>Our results indicate that TRX improves hepatic lipid metabolism and insulin sensitivity in peripheral tissues. As well as ameliorating oxidative stress, TRX can reduce ectopic lipid deposition, affect genes involved in lipid metabolism, and influence the activity of CYP family enzymes.
url https://doi.org/10.1371/journal.pone.0220377
work_keys_str_mv AT hanamalinska beneficialeffectsoftroxerutinonmetabolicdisordersinnonobesemodelofmetabolicsyndrome
AT martinahuttl beneficialeffectsoftroxerutinonmetabolicdisordersinnonobesemodelofmetabolicsyndrome
AT olenaoliyarnyk beneficialeffectsoftroxerutinonmetabolicdisordersinnonobesemodelofmetabolicsyndrome
AT irenamarkova beneficialeffectsoftroxerutinonmetabolicdisordersinnonobesemodelofmetabolicsyndrome
AT martinporuba beneficialeffectsoftroxerutinonmetabolicdisordersinnonobesemodelofmetabolicsyndrome
AT zuzanaracova beneficialeffectsoftroxerutinonmetabolicdisordersinnonobesemodelofmetabolicsyndrome
AT ludmilakazdova beneficialeffectsoftroxerutinonmetabolicdisordersinnonobesemodelofmetabolicsyndrome
AT rostislavvecera beneficialeffectsoftroxerutinonmetabolicdisordersinnonobesemodelofmetabolicsyndrome
_version_ 1714806070660038656